Investor Relations

Contact us:

Investor Contact:
Ashley R. Robinson
Managing Director
LifeSci Advisors, LLC
617-535-7742
arr@lifesciadvisors.com

Company Contact:
Frank Haluska, M.D., Ph.D.
President and Chief Executive Officer
info@anchiano.com

We are located in Cambridge, MA, and in Jerusalem, Israel, and are publicly traded on the Nasdaq (NASDAQ: ANCN).

 

Stock Quote

Nasdaq

Intraday delay: 15 minutes

Stock Chart 

Intraday delay: 15 minutes

Press Releases

Anchiano Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update (November 15, 2019)
Anchiano Discontinues Phase 2 Codex Study Evaluating Inodiftagene Vixteplasmid in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC); Company Focuses on Advancing Pan-RAS Inhibitor Program (November 15, 2019)
Anchiano Therapeutics Chairman Stephen Hoffman Steps Down from Board (October 24, 2019)
Anchiano Therapeutics Enters Into An Exclusive Option To License Agreement for Novel Pan-RAS Inhibitor and PDE10/β-catenin Inhibitor Programs (September 23, 2019)
Anchiano Therapeutics to Present at the Baird 2019 Global Healthcare Conference (September 20, 2019)
Anchiano Therapeutics Reports Second Quarter 2019 Financial Results (August 5, 2019)
Anchiano Therapeutics Delists Ordinary Shares from the Tel Aviv Stock Exchange (June 18, 2019)
Anchiano Therapeutics Announces Appointment of Salar Roshan as Head of Business Development (May 29, 2019)
Anchiano Therapeutics Reports First Quarter 2019 Financial Results (May 22, 2019)
Anchiano Therapeutics to Present at the Oppenheimer 29th Annual Healthcare Conference (March 14, 2019)
Anchiano Therapeutics Initiates Process to Voluntarily Delist its Ordinary Shares from the Tel Aviv Sock Exchange (March 14, 2019)
Anchiano Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results  (March 12, 2019)
Anchiano Therapeutics Announces Closing of $30.5 Million Initial Public Offering  (February 14, 2019)
Anchiano Therapeutics Announces Pricing of $30.5 Million Initial Public Offering  (February 12, 2019)
Anchiano Therapeutics Announces Filing of F-1 Registration Statement for U.S. Initial Public Offering (January 7, 2019)
Anchiano Therapeutics Announces Initiation of Its Pivotal Codex Study of Inodiftagene Vixteplasmid in Patients with Non-Muscle-Invasive Bladder Cancer (November 26, 2018)
Anchiano Therapeutics Announces Appointment of Dr. David Kerstein as New Chief Medical Officer (November 26, 2018)

READ MORE

SEC Company Filings


Filing DateFormDescriptionDownload
11/21/196-KReport of foreign issuer [Rules 13a-16 and 15d-16]PDF
11/15/196-KReport of foreign issuer [Rules 13a-16 and 15d-16]PDF
11/12/196-KReport of foreign issuer [Rules 13a-16 and 15d-16]PDF
10/28/196-KReport of foreign issuer [Rules 13a-16 and 15d-16]PDF
9/23/196-KReport of foreign issuer [Rules 13a-16 and 15d-16]PDF
8/13/196-KReport of foreign issuer [Rules 13a-16 and 15d-16]PDF
8/6/196-KReport of foreign issuer [Rules 13a-16 and 15d-16]PDF
7/22/19S-8Securities to be offered to employees in employee benefit plansPDF
7/8/196-KReport of foreign issuer [Rules 13a-16 and 15d-16]PDF
6/18/196-KReport of foreign issuer [Rules 13a-16 and 15d-16]PDF
5/28/196-KReport of foreign issuer [Rules 13a-16 and 15d-16]PDF
5/22/196-KReport of foreign issuer [Rules 13a-16 and 15d-16]PDF
4/24/1920-F/A[Amend] Annual and transition report of foreign private issuers [Sections 13 or 15(d)]PDF
3/25/1920-KAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]PDF
3/14/196-KReport of foreign issuer [Rules 13a-16 and 15d-16]PDF
3/12/196-KReport of foreign issuer [Rules 13a-16 and 15d-16]PDF
2/14/196-KReport of foreign issuer [Rules 13a-16 and 15d-16]PDF
2/13/19424B4Prospectus [Rule 424(b)(4)]PDF
2/12/196-KReport of foreign issuer [Rules 13a-16 and 15d-16]PDF
2/11/19F-1/A[Amend] Registration statement for certain foreign private issuersPDF
2/8/198-A12BRegistration of securities [Section 12(b)]PDF
2/8/19F-1/A[Amend] Registration statement for certain foreign private issuersPDF
2/7/19F-1/A[Amend] Registration statement for certain foreign private issuersPDF
1/30/19F-1/A[Amend] Registration statement for certain foreign private issuersPDF
1/7/19F-1Registration statement for certain foreign private issuers PDF
Anchiano Therapeutics Ltd. CIK#: 0001534248 (see all company filings)

Contact Investor Relations

Ashley Robinson, LifeSci Advisors
Email: arr@lifesciadvisors.com

Presentations

Ladenburg Thalmann 2019 Heathcare Conference | September 24, 2019

Click here for webcast 

Corporate Update Call | September 24, 2019

Link

Baird’s 2019 Global Healthcare Conference | September 5, 2019

Click here for webcast 

MIXiii-BIOMED 2019 | May 16, 2019 

Oppenheimer 29th Annual Healthcare Conference | March 20, 2019